消癌平联合XELOX方案化疗治疗中晚期转移性胃腺癌的疗效和安全性探讨  

Efficacy and safety of xiaoaiping combined with XELOX regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma

作　　者：阎欣[1] 张倩馨[1] 李萍[1] 曲范杰[1] Yan Xin;Zhang Qianxin;Li Ping;Qu Fanjie.(Department of Medical Oncology, the Third People＇s Hospital of Dalian, Dalian 116033, China)

机构地区：[1]大连市第三人民医院肿瘤内科,116033

出　　处：《中国医师进修杂志》2018年第5期413-417,共5页Chinese Journal of Postgraduates of Medicine

摘　　要：目的探讨消癌平联合XELOX（奥沙利铂＋卡培他滨）方案化疗治疗中晚期转移性胃腺癌的疗效和安全性。方法选取临床确诊的中晚期转移性胃腺癌、KPS评分≥60分，预计生存时间≥3个月的患者62例，采取随机、平行、开放对照试验设计，将患者分为试验组和对照组，每组31例，试验组接受消癌平联合XELOX方案化疗，对照组单用XELOX方案化疗，21d为1个周期，观察两组患者的疗效和不良反应。结果试验组和对照组可评价临床疗效的患者分别为29例和27例。试验组和对照组患者的有效率分别为48．3％（14／29）和33．3％（9，27），疾病控制率分别为89．7％（26／29）和74．1％（20／27），试验组患者的有效率和疾病控制率均明显高于对照组，差异有统计学意义（P〈0．05）。试验组和对照组的中位无进展生存时间分别为6．3和5．1个月，差异有统计学意义（P=0．041）；试验组和对照组患者的中位总生存时间分别为9．6和7．4个月，差异有统计学意义（P=0．029）。两组患者常见的不良反应为恶心呕吐、手足综合征、中性粒细胞减少、白细胞减少、肝功能损害、神经毒性、口腔黏膜炎和腹泻等，其中试验组患者恶心呕吐、中性粒细胞减少、白细胞减少、腹泻的发生率明显低于对照组，差异有统计学意义（P〈0．05）。结论消癌平联合XELOX方案化疗治疗中晚期转移性胃腺癌患者，可明显提高近期疗效，延长患者生存时间，降低化疗不良反应，给患者带来临床受益。Objective To evaluate the efficacy and safety of xiaoaiping combined with XELOX （oxaliplatin and capeeitabine） regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma. Methods This was a randomized, open label and parallel controlled study. Sixty-two advanced metastatic gastric adenocarcinoma patients with KPS score≥60 scores and expected survival time ≥ 3 months were enrolled. The patients were divided into experiment group and control group with 31 cases each. The patients in experiment group received xiaoaiping combined with XELOX regimen chemotherapy, and the patients in control group received XELOX regimen chemotherapy, 21 d was a cycle. The efficacy and adverse events were observed and compared. Results Twenty-nine patients in experiment group and 27 in control group completed treatment. The response rate and disease control rate in experiment group were significantly higher than those in control group： 48.3% （14/29） vs. 33.3% （9/27） and 89.7% （26/29） vs. 74.1% （20/27）, and there were statistical differences （P〈0.05）. The median progression-free survival time in experiment group was significantly longer than that in control group： 6.3 months vs. 5.1 months, and there was statistical difference （P = 0.041）. The median overall survival time in experiment group was significantly longer than that in control group： 9.6 months vs. 7.4 months, and there was statistical difference （P = 0.029）. The most common adverse events in 2 groups were nausea vomiting, hand-foot syndrome, neutropenia thrombocytopenia, leucocytopenia, hepatic functional lesion,neurotoxicity, oral mucositis and diarrhea. The incidences of nausea vomiting, neutropenia thrombocytopenia, leucocytopenia and diarrhea in experiment group were significantly lower than those in control group, and there were statistical differences （P 〈 0.05）. Conclusions Xiaoaiping combined with XELOX regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma can obvio

关 键 词：腺癌 药物疗法 联合 肿瘤转移 消癌平 奥沙利铂 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]